Clinical TrialMay 11, 2026, 10:07 AM
Cytokinetics' MYQORZO Data Reinforces Favorable Clinical Profile, Safety
AI Summary
Cytokinetics announced new data from SEQUOIA-HCM, MAPLE-HCM, and FOREST-HCM trials, reinforcing MYQORZO's clinical profile and long-term safety at the ESC Heart Failure 2026 Congress. The analyses showed MYQORZO outperformed metoprolol across sex and doses, demonstrated long-term safety without increased arrhythmia incidence, and positively affected left atrium remodeling. Additionally, real-world evidence highlighted the significant burden of hypertrophic cardiomyopathy (HCM) and the unmet need for effective therapies.
Key Highlights
- MYQORZO improved peak oxygen consumption by +2.2 mL/kg/min for both sexes in MAPLE-HCM.
- Long-term MYQORZO treatment (up to 96 weeks) did not increase arrhythmia incidence in FOREST-HCM.
- Chinese oHCM patients saw significant LVOT gradient reductions of -40.3 mmHg (resting) and -45.6 mmHg (Valsalva).
- MYQORZO significantly improved left atrial reservoir strain by +2.9% and conduit strain by +2.2%.
- MYQORZO reduced left atrial volume index by -3.5 mL/m2 in SEQUOIA-HCM.
- oHCM patients reported 26.6% activity impairment, highlighting the significant unmet need.
- 70% of nHCM patients on guideline-directed medical therapy still experienced substantial clinical burden.
Price Impact
More from CYTK